HIV Window Period | STD TESTING SINGAPORE™
HIV Window Period | STD TESTING SINGAPORE™ @stdtestingsingapore_com: HIV (human immunodeficiency virus) window period, Singapore. Private & confidential service.
Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
| SHIM CLINIC|
STD TESTING SINGAPORE™
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: HIV Window Period | STD TESTING SINGAPORE™
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Table of Contents HIV window period is the time from HIV infection until a HIV Test can detect any change. Within the HIV window period, the HIV Test would be negative. During this period, the HIV viral load is extremely high, thus making the person highly infectious.
References HIV is the abbreviation for the human immunodeficiency virus, which causes the acquired immunodeficiency syndrome
- 4 weeks after exposure, a negative 4th generation HIV ELISA Test "is very reassuring / highly likely to exclude HIV infection."
- 12 weeks after exposure, a negative 3rd generation HIV ELISA Test "would definitively exclude HIV infection."
HIV symptoms which may present in acute HIV infection: These are nonspecific symptoms and can present with other infections; consequently, they are unreliable indicators of HIV infection.
Remember, there is no HIV cure.
| Notes || Sampling Method |
Time to Results
Cost / Price
| 0-72 hours |
No test available
| || |
| 2 weeks (as short as 10-12 days) |
HIV DNA test
- A PCR (polymerase chain reaction) NAT (nucleic acid test) for HIV-1 proviral DNA, therefore a HIV DNA Test.
- Method: Proviral DNA Polymerase Chain Reaction (Roche Amplicor HIV-1 DNA Test, V1.5) This test uses primers SK145 and SKCC1B to define a sequence of 155 nucleotides within a highly conserved region of the HIV-1 gag gene.
- Usually used for the early diagnosis of HIV infection in neonates born to HIV+ mothers. As maternal antibodies circulate in the child for several months, the HIV antibody test would be positive.
- Also used for early HIV diagnosis in adults.
| 1 month |
HIV combo test
| || Fingerprick |
HIV rapid test
| 1 month |
HIV duo test
| || Venipuncture|
| 3 months |
| || HIV oral test /|
HIV saliva test /
HIV rapid test
| 3 months |
HIV blood test
| || Venipuncture |
HIV western blot test
| || Venipuncture |
HIV RNA test
| || Venipuncture|
HIV ELISA (Enzyme-linked immunosorbent assay) test generations:
References HIV rapid test (20 minutes to results) Two types are available:
- 1st generation: HIV-1 IgG antibody
- 2nd generation: HIV-1 & HIV-2 IgG antibodies
- 3rd generation: HIV-1 & HIV-2 IgG & IgM antibodies
- 4th generation: HIV-1 & HIV-2 IgG & IgM antibodies and HIV p24 antigen
Note: If the clinic attendance is only for the HIV rapid test, then consultation fees are not added.
References HIV PCR (polymerase chain reaction) NAT (nucleic acid test) HIV Risk (2009 figures)
Estimated HIV transmission risk per exposure for specific activities and events
Sources: vaginal sex;1 anal sex;2 fellatio;3 2 mother-to-child;4 other activities.5
|Activity ||Risk-per-exposure |
|Vaginal sex, female-to-male, studies in high-income countries ||0.04% (1:2380) |
|Vaginal sex, male-to-female, studies in high-income countries ||0.08% (1:1234) |
|Vaginal sex, female-to-male, studies in low-income countries ||0.38% (1:263) |
|Vaginal sex, male-to-female, studies in low-income countries ||0.30% (1:333) |
|Vaginal sex, source partner is asymptomatic ||0.07% (1:1428) |
|Vaginal sex, source partner has late-stage disease ||0.55% (1:180) |
|Receptive anal sex amongst gay men, partner unknown status ||0.27% (1:370) |
|Receptive anal sex amongst gay men, partner HIV positive ||0.82% (1:123) |
|Receptive anal sex with condom, gay men, partner unknown status ||0.18% (1:555) |
|Insertive anal sex, gay men, partner unknown status ||0.06% (1:1666) |
|Insertive anal sex with condom, gay men, partner unknown status ||0.04% (1:2500) |
|Receptive fellatio ||Estimates range from 0.00% to 0.04% (1:2500) |
|Mother-to-child, mother takes at least two weeks antiretroviral therapy ||0.8% (1:125) |
|Mother-to-child, mother takes combination therapy, viral load below 50 ||0.1% (1:1000) |
|Injecting drug use ||Estimates range from 0.63% (1:158) to 2.4% (1:41) |
|Needlestick injury, no other risk factors ||0.13% (1:769) |
|Blood transfusion with contaminated blood ||92.5% (9:10) |
HIV Risk (2005 figures)
- Boily MC et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9(2): 118-129, 2009
- Vittinghoff E et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. American Journal of Epidemiology 150: 306-311, 1999
- Del Romero J et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 16(9): 1296-1297, 2002
- Townsend C et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981, 2008
- Baggaley RF et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion. AIDS 20: 805-812, 2006
- HIV & AIDS Information :: How transmission occurs - Estimated risk per exposure
Estimated per-act risk for acquisition of HIV, by exposure route*
*Estimates of risk for transmission from sexual exposures assume no condom use.
|Exposure route||Risk per 10,000|
to an infected source
|Needle-sharing injection-drug use||67||0.67|
|Receptive anal intercourse||50||0.5|
|Percutaneous needle stick||30||0.3|
|Receptive penile-vaginal intercourse||10||0.1|
|Insertive anal intercourse||6.5||0.065|
|Insertive penile-vaginal intercourse||5||0.05|
|Receptive oral intercourse†||1||0.01|
|Insertive oral intercourse†||0.5||0.005|
†Source refers to oral intercourse performed on a man.
References HIV risk (2002 figures)
HIV Risk Statistics (chances of getting HIV)
|HIV Risk Factors ||HIV Transmission Probability |
|Needle stick injury3 ||1/300 |
|Receptive anal intercourse4 ||1/100 |
|Receptive vaginal intercourse5 ||1/1000 |
|Insertive vaginal intercourse4 ||1/2000 |
|Insertive anal intercourse4 ||1/2500 |
|Receptive fellatio with ejaculation4 ||1/2500 |
|Sharing needles6 ||1/150 |
HIV prevention / HIV PEP (post-exposure prophylaxis) treatment can prevent you from getting an HIV infection, and turning HIV positive.
- Cardo DM, Culver DH, Ciesielski CA, et al. A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure. N Engl J Med. 1997;337:1485-1490.
- Katz MH, Gerberding JL. Management of occupational and nonoccupational postexposure HIV prophylaxis. Current Inf Dis Reports. 2002;4:543-549.
- Gerberding JL. Prophylaxis for Occupational Exposure to HIV. Ann Intern Med. 1996;6:497-501
- Vitinghoff E, Douglas J, Judon F, et al. Per-Contact Risk of Human Immunodificiency Virus Transmision between Male Sexual Partners. Am J Epidemiol. 1999;150:306-311.
- Peterman TA, Stoneburner RL, Allen JR, et al. Risk of Human Immunodeficiency Virus Transmission From Heterosexual Adults With Transfusion-Associated Infections. JAMA. 1988;259:55-58. [Erratum. JAMA. 1989;262:502]
- Kaplan EH, Heimer R. A Model-Based Estimate of HIV Infectivity via Needle Sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.
Individuals are eligible for HIV PEP Treatment if all the following criteria are met:
Prompt antiviral therapy may reduce the risk of HIV transmission by as much as 80%.
- less than 72 hours has elapsed since exposure;
- the exposed individual is not known to be HIV infected;
- the person who is the source of exposure is HIV infected or has unknown HIV status;
- mucous membrane or non-intact skin was exposed to a potentially infectious body fluid;
For optimal efficacy, antiretroviral therapy should be started as soon as possible, ideally within 1 hour of exposure. So that you can remain HIV negative.
The medications and dosages are the same as those used for lifelong treatment of HIV patients. However, for HIV PEP treatment, it is taken for only a month.
References Drugs commonly used in HIV PEP: References TORCH
(of HIV/STD/pregnancy), and what you can do before and after exposure.
Wnt/β-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1.
Thu, 31 Jul 2014 19:45:02 +0100 | Genetics and Molecular Research
Authors: Cheng BQ, Jiang Y, Zhu Q, Lin WG
Breaking Open Public Places: UNFPA Launches Coolibah - 21 July 2014
Thu, 31 Jul 2014 15:36:28 +0100 | UNFPA News
MELBOURNE, Australia – At the International AIDS Conference 2014 today, UNFPA, the United Nations Population Fund, launched a youth networking zone called the coolibah, where, throughout the week, it will host a range of activities for and with young people, including a series of luncheons with leaders in the field of HIV and AIDS. (Source: UNFPA News)
UNFPA engages young people in the fight against HIV - 21 July 2014
Thu, 31 Jul 2014 15:36:28 +0100 | UNFPA News
MELBOURNE, Australia – Every hour, about 80 young people are newly infected with HIV, according to the recently released Gap Report by UNAIDS. The participation and leadership of young people will therefore be critical in bringing the global HIV epidemic to an end. Today, at the 20th International AIDS Conference, UNFPA launched a youth networking zone called the ‘coolibah’, where young people will be able to speak with leaders in the field of HIV and AIDS. (Source: UNFPA News)
Hearing Aids Market Analysis by Product (Behind-The-Ear Aids,...
Thu, 31 Jul 2014 13:25:08 +0100 | PRWeb: Medical Pharmaceuticals
Market Size - $4,369.3 mn in 2013, Market Growth – CAGR of 3.2%, Market Trends – Rapidly growing adoption rates of 100% digital hearing aid technology. View full report with TOC -...(PRWeb July 30, 2014)Read the full story at http://www.prweb.com/releases/Hearing_Aids_Market_Size/Industry_Trends_Analysis/prweb12058370.htm (Source: PRWeb: Medical Pharmaceuticals)
Repeat Antenatal HIV Testing in the Third TrimesterRepeat Antenatal HIV Testing in the Third Trimester
Thu, 31 Jul 2014 12:12:16 +0100 | Medscape Today Headlines
Should a repeat HIV test be performed in the third-trimester of pregnancy? HIV Medicine (Source: Medscape Today Headlines)
Africa: The 'Sex-On-Site' Venues Tour - Queer Melbourne's Erotic Otherworld
Thu, 31 Jul 2014 09:31:09 +0100 | AllAfrica News: HIV-Aids and STDs
[Daily Maverick]Picture going on a tour of venues where people go specifically to have sex. Usually with strangers. In all kinds of unusual ways. But, it seems, whatever they're doing, they're awfully hygienic about it. Seem like an unusual way to spend a morning? REBECCA HODES actually did it. The tour, that is. Strictly business. (Source: AllAfrica News: HIV-Aids and STDs)
Mozambique: First Lady Begins Working Visit to Zambezia
Thu, 31 Jul 2014 07:34:56 +0100 | AllAfrica News: HIV-Aids and STDs
[AIM]Quelimane, Mozambique -Mozambican First Lady Maria da Luz Guebuza on Monday arrived in Quelimane, the provincial capital of Zambezia, at the beginning of a two day working visit. (Source: AllAfrica News: HIV-Aids and STDs)
Functional assessment of multivessel coronary artery disease: ischemia-guided percutaneous coronary intervention
Thu, 31 Jul 2014 07:20:06 +0100 | Coronary Artery Disease
Invasive evaluation and treatment of coronary artery disease (CAD) has traditionally been based upon coronary angiography to determine the need for and the success of revascularization. However, coronary angiography augmented with fractional flow reserve (FFR) creates a paradigm shift, providing a more complete functional assessment of coronary lesions. Measuring FFR to identify ischemic lesions and guide revascularization results in fewer adverse outcomes, including persistent angina, myocardial infarction, and mortality. An ischemic lesion identified by FFR is more likely to lead to adverse events when compared with an angiographically similar lesion with nonischemic FFR when both are treated medically. Although the mechanism explaining this is unclear, it is likely multifactorial, inclu...
Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi
Thu, 31 Jul 2014 04:00:00 +0100 | EurekAlert! - Medicine and Health
(Elizabeth Glaser Pediatric AIDS Foundation) Today the Elizabeth Glaser Pediatric AIDS Foundation and Riders for Health announced a new partnership that will expedite the delivery of laboratory samples and HIV-related test results to health facilities in two districts of the Northern and Central Zones of Malawi. (Source: EurekAlert! - Medicine and Health)
Thu, 31 Jul 2014 00:14:30 +0100 | Support for International Change : HIV AIDS
Habari zenu? (How are you?)